JBIO (STOCKS)
Jade Biosciences, Inc. Common Stock
$23.810000
+0.600000 (+2.59%)
Prev close: $23.210000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Tom Frohlich
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,835.29M
- Employees
- 55
- P/E (TTM)
- -8.88
- P/B (TTM)
- 3.35
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.57 | $-0.49 | -0.0777 | -15.78% |
|
Dec 2025 (Q4)
|
$-0.59 | $-0.48 | -0.1064 | -21.96% |
|
Sep 2025 (Q3)
|
$-0.48 | $-0.69 | +0.2075 | +30.18% |
|
Jun 2025 (Q2)
|
$-0.86 | $-0.44 | -0.4186 | -94.83% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $11.59M |
| Operating Expenses | $164.74M |
| Research and Development | $136.67M |
| Other Operating Expenses | $28.07M |
| Operating Income/Loss | -$164.74M |
| Income/Loss From Continuing Operations After Tax | -$153.24M |
| Income/Loss From Continuing Operations Before Tax | -$153.15M |
| Income Tax Expense/Benefit | $89.00K |
| Net Income/Loss | -$153.24M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$153.24M |
| Net Income/Loss Available To Common Stockholders, Basic | -$141.96M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | -$11.28M |
| Preferred Stock Dividends And Other Adjustments | -$11.28M |
| Basic Earnings Per Share | -$1.92 |
| Diluted Earnings Per Share | -$1.92 |
| Basic Average Shares | 165,955,801 |
| Diluted Average Shares | 165,955,801 |
| Assets | $472.11M |
| Current Assets | $471.25M |
| Noncurrent Assets | $862.00K |
| Fixed Assets | $144.00K |
| Other Non-current Assets | $718.00K |
| Liabilities | $32.20M |
| Current Liabilities | $31.57M |
| Accounts Payable | $6.58M |
| Wages | $3.93M |
| Other Current Liabilities | $21.07M |
| Noncurrent Liabilities | $628.00K |
| Equity | $439.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $439.92M |
| Liabilities And Equity | $472.11M |
| Net Cash Flow From Operating Activities | -$123.51M |
| Net Cash Flow From Operating Activities, Continuing | -$123.51M |
| Net Cash Flow From Investing Activities | -$352.97M |
| Net Cash Flow From Investing Activities, Continuing | -$352.97M |
| Net Cash Flow From Financing Activities | $362.89M |
| Net Cash Flow From Financing Activities, Continuing | $362.89M |
| Net Cash Flow | -$113.59M |
| Net Cash Flow, Continuing | -$113.59M |
| Comprehensive Income/Loss | -$153.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$153.88M |
| Other Comprehensive Income/Loss | -$165.00K |